Brief: BioXcel Therapeutics Says Phase 2A Trial Enrollment Expected In H1 2025

BioXcel Therapeutics

15/10/2024 12:11

Oct 15 (Reuters) - BioXcel Therapeutics Inc  BTAI.O :
    * BIOXCEL THERAPEUTICS ANNOUNCES U.S. DEPARTMENT OF DEFENSE
GRANT
TO UNIVERSITY OF NORTH CAROLINA TO FUND STUDY OF BXCL501
(SUBLINGUAL DEXMEDETOMIDINE) FOR TREATING ACUTE STRESS DISORDER
    * BIOXCEL THERAPEUTICS INC - PHASE 2A TRIAL ENROLLMENT
EXPECTED IN
H1 2025
    * BIOXCEL THERAPEUTICS INC - DOD AWARDS $2.8 MILLION TO UNC
FOR
BXCL501 TRIAL

Source text for Eikon:  ID:nGNX4HcyYv 
Further company coverage:  BTAI.O 

 ((Reuters.Briefs@thomsonreuters.com;))